Solid Biosciences to Present at Barclays Global Healthcare Conference
March 07, 2023 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences to Present at SVB Securities Global Biopharma Conference
February 08, 2023 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDA’s Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrophy
January 26, 2023 08:00 ET
|
Solid Biosciences Inc.
- Publication in Human Gene Therapy provides rationale for the use of microdystrophin expression levels as a surrogate endpoint reasonably likely to predict clinical benefit for AAV gene therapy...
Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases
January 11, 2023 08:00 ET
|
Solid Biosciences Inc.
Research collaboration to target severe form of genetic dilated cardiomyopathyCollaboration strengthens Solid Biosciences’ scientific capabilities and commercial potential in cardiac...
Solid Biosciences Outlines Strategy for Leadership in Precision Genetic Medicines with Focus on Neuromuscular and Cardiac Diseases
January 10, 2023 08:00 ET
|
Solid Biosciences Inc.
– Investigational New Drug (IND) application for SGT-003, next-generation gene therapy for Duchenne muscular dystrophy utilizing novel capsid AAV-SLB101, expected in 2H-2023 – – Candidate selection...
Solid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer
January 09, 2023 16:26 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer
January 09, 2023 08:01 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 09, 2023 08:00 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2022 16:35 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for patients with neuromuscular and...
Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement
December 05, 2022 07:30 ET
|
Solid Biosciences Inc.
- Transactions create a precision genetic medicine company focused on neuromuscular and cardiac diseases, led by industry veteran Bo Cumbo - - Company to leverage synergies and key assets, including...